Category: Pharma Industry

Drug Maker Owes 340B Providers Repayment, HRSA Pending Audit Finds

August 22, 2023 Rich Daly, Editor in Chief Views

A HRSA fiscal year 2023 audit tentatively found that drug maker Nephron Pharmaceuticals owes 340B repayments to providers.

The first posted fiscal year 2023 audit of a drug maker tentatively found the company owes repayments to providers. The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Drugs Among Those at Tornado-Hit Facility Requiring Direct Purchase

August 22, 2023 Rich Daly, Editor in Chief Views

Pfizer has limited multiple 340B-eligible drugs to direct purchase after a tornado damaged one of the drug maker's manufacturing facilities.

Federal officials confirmed that 340B-eligible drugs are among the 12 medications pharmaceutical manufacturer Pfizer has limited to direct purchase after [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Share of Retail Pharmacies that Contract with ‘Core’ 340B Safety-Net Facilities Fell Over Time, Study Finds

August 17, 2023 Tom Mirga, Editor at Large Views

There has been a decline in the share of retail pharmacies that contract with 340B "core safety-net facilities," according to a JAMA Health Forum study.

The proportion of retail contract pharmacies in the 340B program that contract exclusively with “core safety-net” facilities fell from 95% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

HHS Asks Court to Deny Injunction Against Medicare Drug Price Negotiations

August 17, 2023 Tom Mirga, Editor at Large Views

HHS asked the U.S. District Court in Dayton, Ohio to deny a preliminary injunction that would prevent Medicare drug price negotiations.

The U.S. Department of Health and Human Services (HHS) asked a federal court to deny a preliminary injunction sought by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Pfizer Changes Costly Cardiac Drugs’ Access Rules for 340B Providers

August 17, 2023 Tom Mirga, Editor at Large Views

Pfizer has limited multiple 340B-eligible drugs to direct purchase after a tornado damaged one of the drug maker's manufacturing facilities.

Drug manufacturer Pfizer is changing how healthcare providers access 340B pricing on two expensive, related heart medicines, effective Nov. 1, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two Drug Makers Post Manufacturer Notices for 340B Overcharges

August 17, 2023 William Newton, Associate Editor/Senior Writer Views

Meitheal Pharmaceuticals and Purdue Pharma are each sending 340B covered entities refunds for overcharges totaling $100 or more.

Two drug manufacturers are sending 340B covered entities refunds for overcharges totaling $100 or more, according to public filings posted [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Lobbying Activity Experiences Historic Surge

August 15, 2023 Rich Daly, Editor in Chief Views

Key House Republicans on Tuesday introduced long-awaited—and contentious—legislation to overhaul the 340B program.

The hiring of lobbyists in the congressional legislative fight over 340B was dominated by pharmaceutical firms and provider-manufacturer alliances in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Major Drug Company Sues Louisiana Over 340B Contract Pharmacy Law

August 15, 2023 William Newton, Associate Editor/Senior Writer Views

AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.

Drug manufacturer AstraZeneca, one of the first companies to place restrictions on 340B discounts in the contract pharmacy setting, has [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

GSK Giving 340B Entities Refunds Again for Asthma Medicine Purchases

August 15, 2023 Tom Mirga, Editor at Large Views

Senderra Rx will no longer dispense GlaxoSmithKline’s asthma drug, Nucala.

GlaxoSmithKline is sending 340B covered entities refunds for overcharges totaling $100 or more for purchases of two dosage forms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Five Major Drug Makers Oppose Health Center’s Legal Challenge to 340B Patient Definition

August 8, 2023 Tom Mirga, Editor at Large Views

AbbVie, BMS, Lilly, and Merck jointly asked a federal district court to dismiss a health center’s challenge to the 340B patient definition. Drug maker Janssen asked the same separately.

Drug makers AbbVie, Bristol Myers Squibb, Janssen, Lilly, and Merck asked a federal district court in South Carolina on Friday [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live